New immunotherapy for lung cancer reduces disease progression by 38%

• Facebook
• Twitter
• Reddit
• Tumblr
• LinkedIn
• Pinterest
• RSS Feed
• Link

• Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
• Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
• FDA has mandated a top-level black box warning for all marketed CAR-T therapies
• Can people with high blood pressure eat peanuts?
• What is the difference between dopamine and dobutamine?
• How long can the patient live after heart stent surgery?

New immunotherapy for lung cancer reduces disease progression by 38%.

First-line treatment of lung cancer TIGIT antibody immune combination therapy reduces the risk of disease progression by 38%.

On December 10, 2021, Genentech, a Roche subsidiary, announced that the new cancer immunotherapy tiragolumab targeting TIGIT, combined with the PD-L1 inhibitor atezolizumab, will be the first-line treatment for PD- Positive results were obtained in Phase 2 clinical trials in patients with L1-positive metastatic non-small cell lung cancer (NSCLC).

At a median follow-up time of 2.5 years, the combination of tiragolumab/atilizumab resulted in a significant and continuous improvement in the progression-free survival (PFS) of patients compared with atilizumab monotherapy.

TIGIT (T cell immunoreceptor with Ig and ITIM domains) is called T cell immunoglobulin and ITIM domain protein. It is an immune checkpoint protein mainly expressed on the surface of T cells and natural killer (NK) cells.

The press release states that tiragolumab is the first anti-TIGIT therapy to be granted breakthrough therapy designation by the US FDA.

Blocking the TIGIT signal pathway with tiragolumab may enhance the body’s immune response to cancer cells and improve anti-tumor activity.

The latest results show that when the median follow-up time is 2.5 years:

In the intent-to-treat (ITT) population (n=67), compared with atelizumab monotherapy (median PFS=3.9 months), the tiragolumab/atelizumab combination makes the patient’s disease progression or The risk of death was reduced by 38%, the median PFS was 5.6 months (HR=0.62, 95% CI: 0.42–0.91), and the overall response rate (ORR) was improved (38.8% VS. 20.6%).

Exploratory analysis in patients with high PD-L1 expression (TPS≥50%) (n=29) showed that compared with atelizumab monotherapy (median PFS=4.1 months), patients’ disease The risk of progression or death risk was reduced by 71%, the median PFS was 16.6 months (HR=0.29, 95% CI: 0.15–0.53), and the ORR was significantly improved (69% VS. 24.1%).

In the secondary end point of the overall survival (OS) trial, the tiragolumab/atelizumab combination also brought benefits to the ITT population, with a median OS of 23.2 months (14.5 months for the control group) (HR= 0.69, 95% CI: 0.44–1.07).

The specific results of the test are shown in the table below:

Table source: Reference materials[1]

Dr. Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, said: These encouraging results indicate that the combination of anti-TIGIT antibodies and anti-PD-L1 cancer immunotherapy may represent a new approach to addressing the unmet need for cancer.   We look forward to the results of phase 3 clinical trials in lung cancer and other challenging tumor types.

Reference:

[1] New Data From the Phase II CITYSCAPE Trial Show Encouraging Results With Genentech’s Novel Anti-TIGIT Tiragolumab Plus Tecentriq. Retrieved December 10, 2021

New immunotherapy for lung cancer reduces disease progression by 38%

(source:internet, reference only)

Disclaimer of medicaltrend.org

Important Note: The information provided is for informational purposes only and should not be considered as medical advice.